Disc Medicine (IRON) reported a 2024 loss Thursday of $3.96 per share, wider than a loss of $3.42 a year earlier.

Analysts polled by FactSet expected a loss of $4.13.

As expected, no revenue was reported.

As of Dec. 31, the company had $489.9 million in cash, cash equivalents and marketable securities. Combined with $243.3 million from an underwritten public offering, the company said it expects this will fund its operations into 2028.